Sertacon VS300 mg

Sertacon VS is indicated for the local treatment of vulvovaginal candidiasis (vaginal yeast infection) caused by Candida albicans and other susceptible Candida species.

Established use

• Treatment of acute vulvovaginal candidiasis in adult women, confirmed or strongly suspected on the basis of typical signs and symptoms (vaginal itching, burning, irritation, and a thick, white discharge).

Not established / not indicated

• Sertacon VS is not indicated for bacterial vaginosis, trichomoniasis, or other non-fungal causes of vaginal discharge; these require different treatment and should be ruled out or confirmed by a physician before use.
• Not indicated for use in premenarchal (pre-pubertal) girls.

A physician should confirm the diagnosis before treatment is started, particularly in women with recurrent or persistent symptoms, since several conditions can mimic vulvovaginal candidiasis.

Each vaginal suppository (ovule/pessary) of Sertaconazole Nitrate [Vaginal] contains sertaconazole nitrate as the active pharmaceutical ingredient, in a base suitable for intravaginal insertion, along with pharmaceutically acceptable excipients that assist dissolution and local retention. The exact strength and excipients vary by manufacturer and marketed presentation; refer to the specific product's package insert for the precise strength and inactive ingredients.

Sertacon VS is a topical (locally acting) antifungal medicine belonging to the imidazole class, formulated as a vaginal suppository/ovule for intravaginal use. It is used to treat vaginal yeast (candida) infections.

Unlike many other azole antifungals that are only fungistatic at usual concentrations, Sertacon VS has a dual mechanism: it inhibits fungal ergosterol synthesis (the classical azole mechanism) and, because of its unique benzothiophene ring structure, can also directly disrupt the fungal cell membrane, giving it fungicidal activity against Candida species at the concentrations achieved locally in the vagina.

Systemic absorption after vaginal administration is minimal, so effects and side effects are mainly local (at the site of application) rather than systemic.

Sertacon VS belongs to the imidazole antifungal class and is classified as a vaginal (topical) antifungal / anti-infective preparation, used for local treatment of vulvovaginal candidiasis.

Sertaconazole Nitrate [Vaginal] is an imidazole derivative antifungal. Its primary mechanism, shared with other azole antifungals, is inhibition of the fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, which blocks conversion of lanosterol to ergosterol. Ergosterol is an essential component of the fungal cell membrane; its depletion increases membrane permeability and disrupts fungal cell growth, producing a fungistatic effect.

Sertaconazole Nitrate [Vaginal] additionally contains a benzothiophene ring in its chemical structure that is not present in most other azoles. This allows a second, non-azole mechanism of action: direct insertion into and disruption of the fungal cell membrane lipid bilayer, independent of ergosterol depletion. This dual mechanism gives Sertaconazole Nitrate [Vaginal] fungicidal activity against Candida albicans and several non-albicans Candida species at concentrations achieved with local vaginal application, in addition to activity against dermatophytes and some other fungi.

Following intravaginal administration, systemic absorption of Sertaconazole Nitrate [Vaginal] is minimal, so pharmacokinetic exposure and systemic drug levels are low; the drug acts predominantly at the local (vaginal mucosal) site of application.

Sertacon VS vaginal suppositories are for intravaginal use only and must not be taken by mouth.

• Wash hands before and after insertion.
• Insert the suppository deep into the vagina, preferably while lying on your back with knees bent, using a finger or the applicator supplied with the product (if provided).
• Bedtime application is generally preferred so the medicine remains in place longer and is not lost through leakage while standing or walking.
• Use the entire course as prescribed, even during menstruation, unless a physician advises otherwise; a physician may recommend avoiding vaginal treatment during heavy menstrual flow.
• Avoid sexual intercourse during treatment; if intercourse cannot be avoided, be aware that Sertacon VS suppository bases (particularly oil-based formulations) may weaken latex condoms or diaphragms (see Interactions).
• Do not use tampons while using Sertacon VS, as they may absorb the medicine and reduce its effect.

Because systemic absorption of Sertacon VS after vaginal application is minimal, clinically significant systemic drug-drug interactions are unlikely and have not been well established.

Clinically relevant local interaction

• Latex condoms and diaphragms: the suppository base of some Sertacon VS formulations (particularly oil-based bases) may weaken latex rubber, reducing the effectiveness of latex condoms or diaphragms used for contraception or infection prevention during and shortly after treatment. Check the specific product's labeling, and consider alternative or additional contraceptive protection during treatment and for a few days afterward.

Inform your physician or pharmacist about all other medicines, including other vaginal products, being used at the same time.

Because Sertacon VS acts mainly at the site of application, most reported side effects are local and mild.

Common (local, usually mild and transient)

• Burning sensation at the application site
• Vaginal or vulvar itching or irritation
• Local redness or a feeling of discomfort

Less common

• Pelvic or lower abdominal discomfort
• Skin rash or allergic-type local reaction

If irritation is severe, persistent, or accompanied by signs of an allergic reaction (e.g., significant swelling, spreading rash, difficulty breathing), stop use and seek medical attention promptly.

Pregnancy: Data specific to Sertacon VS in human pregnancy are limited. As with other topical/vaginal azole antifungals, systemic absorption is minimal, and such preparations are generally considered acceptable for use in pregnancy when clearly needed and under medical guidance, particularly beyond the first trimester. Sertacon VS should be used during pregnancy only if a physician judges that the potential benefit justifies the potential risk; use exactly as directed, and manual (finger) insertion rather than an applicator may be advised by the physician in later pregnancy. Always consult a physician before use in pregnancy.

Lactation: It is not known whether vaginally administered Sertacon VS is excreted in human breast milk; because systemic absorption is minimal, risk to a breastfeeding infant is expected to be low, but a physician should be consulted before use while breastfeeding.

• Use Sertacon VS exactly as prescribed by a physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• For vaginal use only; do not swallow, and avoid contact with the eyes.
• Complete the full prescribed course even if symptoms improve early, to reduce the chance of recurrence or resistance.
• Seek medical evaluation if vaginal symptoms do not improve, worsen, or recur frequently, as this may indicate a different infection (e.g., bacterial vaginosis, trichomoniasis) or an underlying condition such as diabetes or immunosuppression.
• Sertacon VS suppository bases (particularly oil-based products) may weaken latex condoms and diaphragms — see Interactions for details.
• Avoid sexual intercourse during treatment where possible.
• Discontinue and consult a physician if signs of local hypersensitivity or an allergic reaction develop (see Side Effects and Contraindications).
• Not intended for use in premenarchal girls or for indications other than vulvovaginal candidiasis diagnosed or confirmed by a physician.

Vaginal overdose with Sertacon VS is unlikely to cause serious systemic toxicity given the minimal systemic absorption from the vaginal route, but using more than the prescribed amount or more frequently than directed does not speed recovery and may increase local irritation.

If a suppository is accidentally swallowed, or if any symptoms suggestive of a systemic reaction occur, seek immediate medical attention or contact a poison control center / emergency services rather than attempting to manage it at home. Take the product packaging with you if seeking medical care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Sertacon VS is not indicated for use in premenarchal (pre-pubertal) girls; safety and efficacy in this population have not been established.

Elderly

Sertacon VS is used in adult women of reproductive and postmenopausal age; no specific dose adjustment is established for elderly patients, but underlying vaginal atrophy or dryness in postmenopausal women should be evaluated by a physician alongside candidiasis treatment.

Renal / hepatic impairment

No specific dose adjustment is established, as systemic absorption after vaginal use is minimal.

Immunocompromised patients / diabetes

Women with poorly controlled diabetes or immunosuppression may have recurrent or more difficult-to-treat candidiasis and should be evaluated by a physician; recurrent infection despite treatment with Sertacon VS warrants medical review.

Sertacon VS for vulvovaginal candidiasis is typically administered as a single-dose vaginal suppository. Depending on the specific product and the physician's assessment, a second single dose may be given after approximately 7 days if symptoms have not fully resolved or the infection is confirmed to persist. The exact duration and whether a repeat dose is needed should be determined by the prescribing physician; do not repeat dosing on your own beyond what is prescribed.

Antifungal agents; Imidazole derivative antifungals; Vaginal anti-infective / antifungal preparations.

Sertaconazole Nitrate [Vaginal] inhibits fungal ergosterol synthesis by blocking the cytochrome P450-dependent enzyme 14-alpha-demethylase, and additionally disrupts the fungal cell membrane directly through its benzothiophene ring structure, giving it fungicidal activity against Candida species at the concentrations achieved with vaginal application.

Sertacon VS is not indicated for use in premenarchal (pre-pubertal) girls; safety and efficacy in this age group have not been established, and this population should be evaluated and treated under the direct supervision of a pediatrician or gynecologist if a fungal vaginal/vulvar infection is suspected.